| News

Vaximm is using AI to develop cancer vaccines

12.11.2019

Basel-based biotech company Vaximm has agreed a collaboration with IT company NEC. Vaximm wants to develop personalized cancer vaccines using NEC’s artificial intelligence (AI)-based prediction system.

Vaccine (Img: PhotoLizM/Pixabay)

According to a press release by Vaximm, Vaximm and NEC have agreed to cooperate on a non-exclusive basis. As part of the collaboration, NEC will make an equity investment in Vaximm. In addition, the Tokyo-based IT company will provide funding for a Phase I clinical trial for personalized neoantigen cancer vaccines.

The two partners want to develop the vaccines through the agreed collaboration. Vaximm will provide its experience in developing oral T-cell immunotherapies for patients, while NEC has developed a neoantigen prediction system based on state-of-the-art artificial intelligence (AI) technology, which is to be utilized in the development of cancer vaccines. Vaximm will manage the clinical trial scheduled for the coming year. NEC has secured the development and commercialization rights to the program worldwide, except for China and other Asian territories, which also apply to Japan.

Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC’s novel AI technology will enable not only the identification but also the prioritization of neoantigens from each patient. Once the list of neoantigens is available, we will be able to apply our technology to quickly produce a personalized vaccine. “

Vaximm is headquartered in the Technology Park, Basel. The location will be pleased to hear another success story from one of its companies based there. This means an extension of the cooperation between NBE Therapeutics and the Czech biotech company Sotio. NBE Therapeutics specializes in developing antibody drug conjugate products for cancer treatment. The two companies want to work together to develop next-generation antibody drug conjugates. Sotio has now exercised the option for developing a second drug candidate. NBE Therapeutics will also be able to use its in-house platform for this, while Sotio has the corresponding commercial rights. The exercise of the option by Sotio will give NBE the right to receive certain payments.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
Startups from the Basel Area ranked among the best
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Startups from the Basel Area ranked among the best

Startups from the Basel Area have been ranked highly in the TOP 100 Swiss Startup Award by Venturelab. The medtech...

Read More
Roche testing for coronavirus and flu simultaneously
Basel Area Business & Innovation, Innovation, Invest

Roche testing for coronavirus and flu simultaneously

The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that...

Read More
Hengrui Medicine sets up clinical research and development in Basel
Basel Area Business & Innovation, Innovation, Invest

Hengrui Medicine sets up clinical research and development in Basel

The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research...

Read More
Polyphor awarded exclusive licensing agreement for China
Basel Area Business & Innovation, Innovation, Invest

Polyphor awarded exclusive licensing agreement for China

The Basel Area-based company Polyphor has signed an exclusive licensing agreement with Fosun Pharma in China. Fosun Pharma will lead...

Read More
New label guarantees that data remains in Switzerland
Basel Area Business & Innovation, Innovation, Invest

New label guarantees that data remains in Switzerland

With the new “swiss hosting” label, the Basel-based company swiss made software Gmbh is guaranteeing that data will not be...

Read More
Coworking in the Basel Area – An Interview with Karin Crisanto
Basel Area Business & Innovation, Switzerland Innovation Park

Coworking in the Basel Area – An Interview with Karin Crisanto

Karin Crisanto recently joined Basel Area Business & Innovation as Head of Innovation Space and Infrastructure. She previously worked for...

Read More
Switzerland ranked in second place globally
Basel Area Business & Innovation, Invest

Switzerland ranked in second place globally

The chemical and pharmaceutical industry of Switzerland has been ranked number two in the world after the USA in terms...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.